Polen Capital Management
XERS icon

Polen Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Polen Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-133,416
Closed -$1.05M – 296
2025
Q4 		$1.05M Buy
133,416
+225
+0.2% +$1.77K ﹤0.01% 133
2025
Q3 		$1.08M Buy
133,191
+197
+0.1% +$1.31K ﹤0.01% 134
2025
Q2 		$621K Buy
+132,994
New +$609K ﹤0.01% 179

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Polen Capital Management's XERS Position: Q1 2026 in Review

Polen Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 133,416 shares — an estimated $1.05M sold.

Polen Capital Management first reported a position in XERS in Q2 2025 and held it in 3 quarters. The position peaked at $1.08M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Polen Capital Management reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
  • Polen Capital Management sold 133,416 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.05M.
  • Polen Capital Management first reported a position in Xeris Biopharma Holdings in Q2 2025 and held it in 3 quarters.
  • Polen Capital Management's Xeris Biopharma Holdings position peaked at $1.08M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Polen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.